These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 11132996)

  • 1. Coronary spastic angina induced by anticholinesterase medication for myasthenia gravis--a case report.
    Suzuki M; Yoshii T; Ohtsuka T; Sasaki O; Hara Y; Okura T; Shigematsu Y; Hamada M; Hiwada K
    Angiology; 2000 Dec; 51(12):1031-4. PubMed ID: 11132996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Coronary vasospasm secondary to hypercholinergic crisis: an iatrogenic cause of acute myocardial infarction in myasthenia gravis.
    Comerci G; Buffon A; Biondi-Zoccai GG; Ramazzotti V; Romagnoli E; Savino M; Rebuzzi AG; Biasucci LM; Loperfido F; Crea F
    Int J Cardiol; 2005 Sep; 103(3):335-7. PubMed ID: 16098399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Current treatment of myasthenia gravis].
    de Assis JL
    Rev Paul Med; 1965 Oct; 67(4):231-42. PubMed ID: 5848156
    [No Abstract]   [Full Text] [Related]  

  • 4. The interaction of human cholinesterases with anticholinesterases used in the therapy of myasthenia gravis.
    Foldes FF; Smith JC
    Ann N Y Acad Sci; 1966 Jan; 135(1):287-301. PubMed ID: 5221345
    [No Abstract]   [Full Text] [Related]  

  • 5. [Myasthenia gravis pseudoparalytica. Clinical picture, pathogenesis, therapy].
    Kunze K
    Med Klin; 1973 Jun; 68(22):723-30. PubMed ID: 4715780
    [No Abstract]   [Full Text] [Related]  

  • 6. Overview of myasthenia gravis.
    Arora Y; Li Y
    Hosp Pract (1995); 2013; 41(4):40-50. PubMed ID: 24145588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacologic enhancement of neuromuscular transmission in myasthenia gravis.
    Riggs JE
    Clin Neuropharmacol; 1982; 5(3):277-92. PubMed ID: 6288236
    [No Abstract]   [Full Text] [Related]  

  • 8. [Cholinergic crisis in a patient with myasthenia treated by plasma exchange and anticholinesterase agents].
    Pourrat O; Robert R; Neau JP; Deleplanque P; Alcalay D
    Ann Med Interne (Paris); 1988; 139 Suppl 1():51-2. PubMed ID: 3247993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coronary spastic angina after the administration of intravenous immunoglobulin in myasthenia gravis: a case report.
    Yanagihashi M; Okamoto R; Morioka H; Sawada M; Matsumoto S; Ikeda T; Kano O
    BMC Neurol; 2020 Aug; 20(1):319. PubMed ID: 32859168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Respiratory form mof myasthenia gravis].
    Fauroux B; Trang H; Renolleau S; Boule M; Barois A; Tournier G
    Arch Fr Pediatr; 1992; 49(7):633-5. PubMed ID: 1476481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Essentials in the management of myasthenia gravis.
    Galdi AP
    Am Fam Physician; 1978 Jun; 17(6):95-102. PubMed ID: 655080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adverse interaction between corticosteroid hormones and anticholinesterase drugs.
    Patten BM; Oliver KL; Engel WK
    Trans Am Neurol Assoc; 1973; 98():248-52. PubMed ID: 4784943
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of myasthenia gravis.
    Flacke W
    N Engl J Med; 1973 Jan; 288(1):27-31. PubMed ID: 4347296
    [No Abstract]   [Full Text] [Related]  

  • 14. Response of myasthenia gravis to rituximab in a patient with non-Hodgkin lymphoma.
    Gajra A; Vajpayee N; Grethlein SJ
    Am J Hematol; 2004 Oct; 77(2):196-7. PubMed ID: 15389902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exacerbation of chronic pancreatitis induced by anticholinesterase medications in myasthenia gravis.
    Tomiyama M; Arai A; Kimura T; Suzuki C; Watanabe M; Kawarabayashi T; Shoji M
    Eur J Neurol; 2008 May; 15(5):e40-1. PubMed ID: 18325026
    [No Abstract]   [Full Text] [Related]  

  • 16. Management of myasthenia gravis.
    Schwendimann RN; Burton E; Minagar A
    Am J Ther; 2005; 12(3):262-8. PubMed ID: 15891271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Value of ipratropium (Atrovent) in the treatment of chronic obstructive lung diseases in myasthenic patients treated with anticholinesterase agents. Apropos of a case].
    Robinet G; Leroyer C; Andre J; Dewitte JD; Clavier J
    Rev Pneumol Clin; 1989; 45(4):161-3. PubMed ID: 2533994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decompensating esophoria as the presenting feature of myasthenia gravis.
    Arblaster GE; Shipman TL; Pepper IM
    J AAPOS; 2009 Jun; 13(3):310-1. PubMed ID: 19395293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The otolaryngologic presentation of myasthenia gravis.
    Carpenter RJ; McDonald TJ; Howard FM
    Laryngoscope; 1979 Jun; 89(6 Pt 1):922-8. PubMed ID: 449537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thyroid gland tumour, pemphigus foliaceus and myasthenia gravis in the daughter of a woman with myasthenia gravis.
    Huh WK; Tada J; Fujimoto W; Toi Y; Arakawa K; Arata J; Morita H; Hamada H
    Clin Exp Dermatol; 2001 Sep; 26(6):504-6. PubMed ID: 11678876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.